Surrogate end points in women's health research: science, protoscience, and pseudoscience
- 30 April 2010
- journal article
- research article
- Published by Elsevier BV in Fertility and Sterility
- Vol. 93 (6), 1731-1734
- https://doi.org/10.1016/j.fertnstert.2009.12.054
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk MarkersObstetrics & Gynecology, 2008
- Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot studyFertility and Sterility, 2007
- Surrogate Endpoints And FDA’s Accelerated Approval ProcessHealth Affairs, 2005
- Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetateJournal of Thrombosis and Haemostasis, 2004
- Biomarker Boom Slowed by Validation ConcernsJNCI Journal of the National Cancer Institute, 2004
- Sex hormone–binding globulin—A surrogate marker for the prothrombotic effects of combined oral contraceptivesAmerican Journal of Obstetrics and Gynecology, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- The Ethics of the Randomized Clinical TrialNew England Journal of Medicine, 1982